Inhaled Nintedanib – dry powder (Avalyn Pharma)

N/A

Report date: 2026/04/07 20:00:20

Base Information

Drug NameInhaled Nintedanib – dry powder (Avalyn Pharma)
Drug Alias NameNintedanib inhalation (Avalyn Pharma)Aerosolized nintedanib (Avalyn Pharma)AP02-DP-Inhaled Nintedanib–dry powder (Avalyn Pharma)AP02-Inhaled Nintedanib (Avalyn Pharma)Nintedanib Solution for Inhalation (Avalyn Pharma) +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 3 antagonistsVascular endothelial growth factor receptor 3 antagonistsFibroblast growth factor receptor 1 antagonists +[10] 
TargetsFibroblast growth factor receptor 3Vascular endothelial growth factor receptor 3Fibroblast growth factor receptor 1 +[10] 
Therapy Area/IndicationsIdiopathic Pulmonary FibrosisPulmonary FibrosisLung Diseases, Interstitial +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaAustralia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAvalyn Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesAvalyn Pharma IncAvalyn Pharma Pty Ltd
Inactive CompaniesN/A
Active IndicationsIdiopathic Pulmonary FibrosisPulmonary FibrosisLung Diseases, Interstitial
Inactive IndicationsRespiratory Tract Diseases

Other Information

ATC CodeN/A
Related LinksN/A